Exploring PROTACs in drug discovery and development
2 Oct 2025Proteolysis targeting chimeras (PROTACs) are able to degrade disease-causing proteins by hijacking the cells own degradation pathway. These molecules are therefore changing the drug discovery landscape by enabling targeting for previously 'undruggable' proteins.
Explore advanced LC-MS bioanalytical solutions that can support your PROTAC workflow to confidently quantify and accelerate development with sensitivity, selectivity and reproducibility.
Related Products
Request Quote for All Products
Andrew+
WatersAndrew+ is based upon 6 years of market feedback, and builds on the success of the Andrew Pipetting Robot. It now enables both fully automated pipetting, as well as the more complex manipulation and grabbing of microplates, tubes and columns, through an expanding range of Andrew+ Accessories. It can also execute protocols designed in OneLab, enabling you to quickly transition from laborious manual procedures to error-free, easily programmable fully-robot workflows.
